Cargando…

Anticoagulation is the answer in treating noncritical COVID-19 patients

All autopsy studies demonstrated widespread thrombosis and alveolar-capillary microthrombi as the cause of death among patients with COVID-19. The autopsy studies are the gold-standard for diagnostic accuracy and therapeutic strategies for any clinical scenarios. The author initially observed that p...

Descripción completa

Detalles Bibliográficos
Autor principal: Kabir, Azad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494147/
https://www.ncbi.nlm.nih.gov/pubmed/34703901
http://dx.doi.org/10.1515/med-2021-0354
_version_ 1784579249527586816
author Kabir, Azad A.
author_facet Kabir, Azad A.
author_sort Kabir, Azad A.
collection PubMed
description All autopsy studies demonstrated widespread thrombosis and alveolar-capillary microthrombi as the cause of death among patients with COVID-19. The autopsy studies are the gold-standard for diagnostic accuracy and therapeutic strategies for any clinical scenarios. The author initially observed that patients already taking therapeutic dose of oral direct factor Xa inhibitors for an unrelated reason, have significantly better survival rates than those not taking any anticoagulants. This influenced the author to conduct a retrospective chart review of the hospitalized patients in Jackson Hospital (Alabama) to evaluate the effect of variable doses of anticoagulation among COVID-19 patients. The study found that serum inflammatory bio-marker D-dimer trends are associated with changes in oxygen requirement among patients with COVID-19, if patients present at an early stage, and titration of Enoxaparin (anticoagulation) dose based on D-dimer trends leads to increased patient survival.
format Online
Article
Text
id pubmed-8494147
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-84941472021-10-25 Anticoagulation is the answer in treating noncritical COVID-19 patients Kabir, Azad A. Open Med (Wars) Research Article All autopsy studies demonstrated widespread thrombosis and alveolar-capillary microthrombi as the cause of death among patients with COVID-19. The autopsy studies are the gold-standard for diagnostic accuracy and therapeutic strategies for any clinical scenarios. The author initially observed that patients already taking therapeutic dose of oral direct factor Xa inhibitors for an unrelated reason, have significantly better survival rates than those not taking any anticoagulants. This influenced the author to conduct a retrospective chart review of the hospitalized patients in Jackson Hospital (Alabama) to evaluate the effect of variable doses of anticoagulation among COVID-19 patients. The study found that serum inflammatory bio-marker D-dimer trends are associated with changes in oxygen requirement among patients with COVID-19, if patients present at an early stage, and titration of Enoxaparin (anticoagulation) dose based on D-dimer trends leads to increased patient survival. De Gruyter 2021-10-05 /pmc/articles/PMC8494147/ /pubmed/34703901 http://dx.doi.org/10.1515/med-2021-0354 Text en © 2021 Azad A. Kabir, published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
Kabir, Azad A.
Anticoagulation is the answer in treating noncritical COVID-19 patients
title Anticoagulation is the answer in treating noncritical COVID-19 patients
title_full Anticoagulation is the answer in treating noncritical COVID-19 patients
title_fullStr Anticoagulation is the answer in treating noncritical COVID-19 patients
title_full_unstemmed Anticoagulation is the answer in treating noncritical COVID-19 patients
title_short Anticoagulation is the answer in treating noncritical COVID-19 patients
title_sort anticoagulation is the answer in treating noncritical covid-19 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494147/
https://www.ncbi.nlm.nih.gov/pubmed/34703901
http://dx.doi.org/10.1515/med-2021-0354
work_keys_str_mv AT kabirazada anticoagulationistheanswerintreatingnoncriticalcovid19patients